Oncolytics publishes pelareorep liver cancer immune response data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. RTX
8. SMCI
9. S
10. COF

Go back to Oncolytics publishes pelareorep liver cancer immune response data

Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy

September 29, 2026 9:30 AM EDT

SAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (Oncolytics or the Company), a clinical-stage immunotherapy company developing pelareorep, today announced data published in the Proceedings of the National Academy of Sciences show pelareoreps ability to change an immunologically inactive liver cancer tumor microenvironment into one that is immunologically active and potentially susceptible to immune-based therapy. The academic paper titled MicroRNA-driven regulation of immunosuppressive microenvironment in hepatocellular carcinoma was published in Proceedings of the National Academy of Sciences on September 28, 2026... More